Inhibition of human immunodeficiency virus type I integrase by naphthamidines and 2-aminobenzimidazoles.
Middleton
Tim
T
Department R47D, Global Pharmaceutical Research and Development, Abbott Laboratories, 200 Abbott Park Rd., Abbott Park, IL 60064-6217, USA. timothy.middleton@abbott.com
Lim
Hock B
HB
Montgomery
Debra
D
Rockway
Todd
T
Tang
Hua
H
Cheng
Xueheng
X
Lu
Liangjun
L
Mo
Hongmei
H
Kohlbrenner
William E
WE
Molla
Akhteruzzaman
A
Kati
Warren M
WM
D001483:Base Sequence; D001562:Benzimidazoles / Q000737:chemistry / Q000494:pharmacology*; D002460:Cell Line; D004279:DNA, Viral / Q000235:genetics; D005814:Genes, Viral; D019427:HIV Integrase / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D019428:HIV Integrase Inhibitors / Q000737:chemistry / Q000145:classification / Q000494:pharmacology*; D015497:HIV-1 / Q000187:drug effects* / Q000201:enzymology* / Q000235:genetics; D006801:Humans; D066298:In Vitro Techniques; D015394:Molecular Structure; D009281:Naphthalenes / Q000737:chemistry / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000737:chemistry / Q000235:genetics / Q000378:metabolism
D001562:Benzimidazoles; D004279:DNA, Viral; D019428:HIV Integrase Inhibitors; D009281:Naphthalenes; D011994:Recombinant Proteins; D019427:HIV Integrase